1-11 of 11
Adam R Craig, MD PhD
Close
Sort by
Journal Articles

Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/mL)

Claire N Harrison, Professor, Aaron T. Gerds, MD MS, Jean-Jacques Kiladjian, MD PhD, Konstanze Döhner, Sarah A Buckley, MD, Jennifer A. Smith, PhD, Adam R Craig, MD PhD, John Mascarenhas, MD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4175.
https://doi.org/10.1182/blood-2019-129245
Published: 2019
Journal Articles

Durable Overall Survival Benefit in Patients ≥ 60 Years with Relapsed or Refractory AML Treated with Vosaroxin/Cytarabine Vs Placebo/Cytarabine: Updated Results from the Valor Trial

Farhad Ravandi, MD, Ellen K. Ritchie, MD, Hamid Sayar, MD, Jeffrey E. Lancet, MD, Michael Craig, MD, Norbert Vey, MD PhD, Stephen A. Strickland, Gary J. Schiller, MD, Elias J. Jabbour, MD, Harry P. Erba, MD PhD, Arnaud Pigneux, MD, Heinz-August Horst, MD PhD, Christian Recher, MD PhD, Virginia M. Klimek, MD, Jorge E. Cortes, MD, Gail J. Roboz, Adam R. Craig, MD PhD, Renee Ward, MD PhD, Jennifer Smith, PhD, Hagop M. Kantarjian, MD, Robert K. Stuart, MD
Journal: Blood
Blood (2016) 128 (22): 903.
https://doi.org/10.1182/blood.V128.22.903.903
Published: 2016
Journal Articles

Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine in the Phase 3 VALOR Study

Jeffrey E Lancet, MD, Farhad Ravandi, MD, Ellen K Ritchie, MD, Hamid Sayar, MD, Stephen A. Strickland, MD, Gary J Schiller, MD, Norbert Vey, MD, Harry P Erba, MD PhD, Arnaud Pigneux, Heinz-August Horst, MD PhD, Christian Recher, MD, Olatoyosi Odenike, MD, Angelo-Michele Carella, MD, Dominik Selleslag, MD, Jonathan Kell, MD, Utz Krug, MD, Leigh Page, Art DeVault, PhD, Shuling Hwang, MD, Adam R Craig, MD PhD, Robert K. Stuart, MD
Journal: Blood
Blood (2015) 126 (23): 2560.
https://doi.org/10.1182/blood.V126.23.2560.2560
Published: 2015
Journal Articles

Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

Naval Daver, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Elias Jabbour, Naveen Pemmaraju, MD, Kenneth Vaughan, Sherry Pierce, BSN, BA, Marina Konopleva, MD PhD, Tapan Kadia, MD, Courtney DiNardo, MD, Gautam Borthakur, MD, Jorge E. Cortes, MD, Adam R Craig, MD PhD, Farhad Ravandi, MD
Journal: Blood
Blood (2015) 126 (23): 461.
https://doi.org/10.1182/blood.V126.23.461.461
Published: 2015
Journal Articles

Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR)

Farhad Ravandi, MD, Ellen Ritchie, MD, Hamid Sayar, MD, Jeffrey Lancet, MD, Michael D. Craig, MD, Norbert Vey, MD, Stephen A. Strickland, MD, Gary Schiller, MD, Elias Jabbour, MD, Harry P. Erba, MD PhD, Arnaud Pigneux, MD, Heinz-August Horst, MD, Christian Recher, MD, Virginia M. Klimek, MD, Jorge Cortes, MD, Eric J. Feldman, MD, Adam R. Craig, MD PhD, Judith A. Fox, PhD, Renee Ward, MD PhD, Jennifer Smith, PhD, Gary Acton, MD, Cyrus Mehta, PhD, Hagop M. Kantarjian, MD, Robert K Stuart, MD
Journal: Blood
Blood (2014) 124 (21): LBA-6.
https://doi.org/10.1182/blood.V124.21.LBA-6.LBA-6
Published: 2014
Journal Articles

Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Chronic Myeloid Leukemia (CML) Patients Who Are Resistant or Intolerant to Two or More Tyrosine Kinase Inhibitors – Results of A Multicenter Phase 2/3 Study.

Jorge Cortes-Franco, MD, Digumarti Raghunadharao, MD, Purvish Parikh, MD, Meir Wetzler, MD, Jeffrey H. Lipton, Dan Jones, MD, PhD, Andreas Hochhaus, MD, Hagop M. Kantarjian, MD, Adam R Craig, MD, PhD, Annie-Claude Benichou, Eric Humphriss, Franck Emmanuel Nicolini, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 861.
https://doi.org/10.1182/blood.V114.22.861.861
Published: 2009
Journal Articles

Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Imatinib-Resistant Chronic Myeloid Leukemia (CML) Patients Who Harbor the Bcr- Abl T315I Mutation–Results of An Ongoing Multicenter Phase 2/3 Study.

Jorge Cortes-Franco, MD, H. Jean Khoury, MD, FACP, Franck Emmanuel Nicolini, MD, PhD, Selim Corm, Jeffrey H. Lipton, MD,PhD, Dan Jones, MD, PhD, Andreas Hochhaus, MD, Adam R Craig, MD, PhD, Annie-Claude Benichou, Eric Humphriss, Hagop Kantarjian, MD
Journal: Blood
Blood (2009) 114 (22): 644.
https://doi.org/10.1182/blood.V114.22.644.644
Published: 2009
Journal Articles

Downregulation of the Common Cytokine Receptor Subunit Beta c by Omacetaxine in CML: A Potential Molecular Mechanism to Overcome Cytokine-Mediated Resistance against BCR-ABL-Inhibitors.

Thomas Klag, MD, Nicolai Härtel, MD, Thomas Schenk, MD, Adam R Craig, MD, PhD, Andreas Hochhaus, MD, Paul La Rosee, MD
Journal: Blood
Blood (2009) 114 (22): 3256.
https://doi.org/10.1182/blood.V114.22.3256.3256
Published: 2009
Journal Articles

Safety and Efficacy of Subcutaneous (SC) Omacetaxine Mepesuccinate in Imatinib(IM)-Resistant Chronic Myeloid Leukemia (CML) Patients (pts) with the T315I Mutation – Results of An Ongoing Multicenter Phase II Study.

Jorge Cortes, MD, H. Jean Khoury, MD, Sélim Corm, MD, Franck E Nicolini, MD, PhD, Jeffrey H. Lipton, MD, PhD, Dan Jones, MD, PhD, Andreas Hochhaus, MD, Adam R Craig, MD, PhD, Annie-Claude Benichou, MD, Eric Humphriss, Hagop Kantarjian
Journal: Blood
Blood (2008) 112 (11): 3239.
https://doi.org/10.1182/blood.V112.11.3239.3239
Published: 2008
Journal Articles

A Phase I Study of INNO-406 in Patients with Advanced Philadelphia (Ph+) Chromosome-Positive Leukemias Who Are Resistant or Intolerant to Imatinib and Second Generation Tyrosine Kinase Inhibitors.

Hagop M. Kantarjian, MD, Jorge Cortes, MD, Philipp le Coutre, MD, Arnon Nagler, MD, Javier Pinilla, MD, Andreas Hochhaus, MD, Dan Jones, MD, PhD, Adam R. Craig, MD, PhD, Eileen Carroll, Oliver G. Ottmann, MD
Journal: Blood
Blood (2007) 110 (11): 469.
https://doi.org/10.1182/blood.V110.11.469.469
Published: 2007
Journal Articles

The ATP Competitor INNO-406 (NS-187) Inhibits Proliferation and Survival of Mouse Cells Expressing Several Immatinib Mesylate Resistant Bcr/Abl Mutants and Cells from CML Patients.

Wenjing Tao, PhD, Tong Sun, MS, Adam R. Craig, MD, PhD, Jorge E. Cortes, MD, Oliver G. Ottmann, MD, Andreas Hochhaus, MD, Premkumar E. Reddy, PhD, Hagop M. Kantarjian, MD, Ralph B. Arlinghaus, PhD
Journal: Blood
Blood (2006) 108 (11): 2179.
https://doi.org/10.1182/blood.V108.11.2179.2179
Published: 2006